SCHEMBL1734405

SCHEMBL1734405

CCNC(=O)c1cc(-c2ccccc2)nc(N(CC)CC)n1

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.70
ADORA1 P30542 7/20 0.45
ADORA2A P29274 4/20 0.45
PIN1 Q13526 1/20 0.44
ADORA3 P0DMS8 3/20 0.43
ADORA2B P29275 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HPGD P15428 2/20 0.42
NPC1 O15118 1/20 0.42
NAPEPLD Q6IQ20 3/20 0.42
P2RY12 Q9H244 2/20 0.42
BRD4 O60885 1/20 0.42
POLB P06746 1/20 0.41
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1733585 0.89 KDM4E (0.66) KDM4EADORA1ADORA2AADORA3ADORA2B
SCHEMBL1734465 0.88 KDM4E (0.72) KDM4EADORA1ADORA2AADORA3ADORA2B
SCHEMBL1734276 0.83 KDM4E (0.61) KDM4EADORA1ADORA2AADORA3ADORA2B
SCHEMBL1733607 0.83 KDM4E (1.00) KDM4EADORA1ADORA2AADORA3ADORA2B
SCHEMBL1734520 0.82 KDM4E (0.74) KDM4EADORA1ADORA2AADORA3ADORA2B
SCHEMBL1734496 0.82 KDM4E (0.74) KDM4EADORA1ADORA2AADORA3ADORA2B
SCHEMBL1733611 0.78 KDM4E (0.83) KDM4EADORA1ADORA2AADORA3ADORA2B
SCHEMBL1733742 0.76 KDM4E (0.85) KDM4EADORA1ADORA2AADORA3ADORA2B
SCHEMBL1734454 0.76 KDM4E (0.85) KDM4EMEN1KMT2AHPGDPOLB
SCHEMBL4697271 0.76 KDM4E (0.65) KDM4EMEN1KMT2AHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
EP-1891018-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals, Inc. (US) 2008-02-27 EP claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
WO-2006127588-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-11-30 WO claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 KDM4E 3910/4885ADORA1 142/4885ADORA2A 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.